Aaron Wealth Advisors LLC Makes New $34,000 Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Aaron Wealth Advisors LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,729 shares of the company’s stock, valued at approximately $34,000.

Several other hedge funds and other institutional investors have also modified their holdings of ALLO. McGlone Suttner Wealth Management Inc. acquired a new position in Allogene Therapeutics during the 4th quarter valued at approximately $27,000. EP Wealth Advisors LLC acquired a new position in shares of Allogene Therapeutics during the third quarter valued at $34,000. GTS Securities LLC bought a new position in shares of Allogene Therapeutics during the third quarter worth about $35,000. Victory Capital Management Inc. bought a new stake in Allogene Therapeutics in the 3rd quarter valued at about $37,000. Finally, Dorsey & Whitney Trust CO LLC acquired a new position in Allogene Therapeutics during the 3rd quarter valued at about $39,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Tuesday, March 19th. JMP Securities restated a “market perform” rating on shares of Allogene Therapeutics in a research report on Friday, January 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 15th. JPMorgan Chase & Co. cut their target price on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 27th. Finally, Guggenheim downgraded Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, January 5th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

Allogene Therapeutics Price Performance

ALLO stock opened at $3.99 on Friday. The company’s 50 day simple moving average is $4.57 and its 200-day simple moving average is $3.53. Allogene Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $6.89. The firm has a market capitalization of $674.68 million, a P/E ratio of -1.91 and a beta of 0.81.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.04. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. Sell-side analysts predict that Allogene Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).